Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALEKONA phase 2 dose-ranging study of GS-5290 in active ulcerative colitis
jRCT2031230403Phase 2Recruiting
- Sponsor
- Gilead Sciences
- Start
- Jan 2024
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of tilpisertib fosmecarbil in autoimmune colitis (4 arms), sponsored by Gilead Sciences. Primary endpoint: Clinical Response. Started Jan 2024; status: recruiting.
02
Drugs
tilpisertib fosmecarbil
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2031230403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230403.